

IMMUNOGEN INC  
Form 8-K  
June 05, 2007

**UNITED STATES**  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **June 4, 2007**

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**

(State or other jurisdiction of incorporation)

**0-17999**

(Commission File Number)

**04-2726691**

(IRS Employer Identification No.)

**128 Sidney Street, Cambridge, MA 02139**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 8.01 OTHER EVENTS**

On June 4, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release on information reported at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 1-5, 2007. The information reported included clinical findings with three compounds that are in human testing that make use of the Company's Tumor-Activated Prodrug (TAP) technology: huC242-DM4 and huN901-DM1, in development by ImmunoGen, and trastuzumab-DM1, in development by the Company's collaborator, Genentech.

Among the information reported was that four of ten patients that received 2.4 or 3.6 mg/kg of trastuzumab-DM1, dosed once every three weeks, had an objective response. These patients all had HER2-expressing metastatic breast cancer that had progressed on a chemotherapy regimen that included Herceptin® (trastuzumab). At the ASCO meeting, Genentech disclosed that they will be initiating a Phase II trial with trastuzumab-DM1 in HER2-expressing metastatic breast cancer. Interim findings were reported from the Company's huC242-DM4 Phase I trial and huN901-DM1 Study 001. The press release noted that the Company expects to begin Phase II evaluation of its huC242-DM4 compound in June/July 2007 and that study center initiation is underway. It also noted that the Company expects to disclose the next steps in the development of its huN901-DM1 compound later in 2007.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Herceptin® is a registered trademark of Genentech.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

<b>Exhibit No.</b>	<b>Exhibit</b>
99.1	Press Release of ImmunoGen, Inc. dated June 4, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: June 5, 2007

/s/ Daniel M. Junius  
Daniel M. Junius  
Executive Vice President and Chief Financial Officer

3

---

**EXHIBIT INDEX**

Exhibit No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated June 4, 2007

4

---